H. Lundbeck (LUN) 43rd Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
43rd Annual J.P. Morgan Healthcare Conference summary
8 Jul, 2026Strategic progress and transformation
Significant progress made on growth, pipeline sustainability, and funding over the past year, with 2024 described as transformative.
Focused Innovator Strategy targets growth of existing assets, building a sustainable late-stage pipeline, and disciplined financial management.
Shift from broad neuropsychiatry to specialized NeuroSpecialty and NeuroRare segments, diversifying the portfolio and emphasizing scientific differentiation.
Strategic brands (Vyepti, Brintellix/Trintellix, Rexulti, Abilify franchise) contributed 75% of revenue, with strong double-digit growth in 9M 2024 and strategic assets growing 21%.
Four assets are expected to be in phase III by 2026, with two already in phase III, supporting long-term growth.
Pipeline and innovation highlights
Vyepti sales expected to triple by 2027, supported by strong commercial execution and expansion into Asian markets.
Rexulti growth driven by new indications, especially agitation associated with dementia in Alzheimer's disease (AADAD), now representing 19% of prescriptions and expected to exceed 20%.
Largest acquisition, bexicaserin, is phase III ready with $1.5–2 billion peak sales potential and patent life to 2041.
Amlenetug, a first-in-class molecule for multiple system atrophy, entered phase III with $1.5–3 billion market potential.
Eight out of nine pipeline programs are in neuro-specialty and neuro-rare, with innovative trial designs and early de-risking strategies accelerating progression.
Financial discipline and capital allocation
Largest capital reallocation in company history (DKK 1+ billion) to fund R&D and growth, targeting 30% adjusted EBITDA and 20–25% R&D investment.
Divestment of Trintellix back to Takeda and other structural initiatives underway, with significant cost ratio improvements expected by 2027.
Healthy financials support ongoing business development, with $1 billion in firepower for tuck-in deals.
R&D investment is increasing to 20-25% of revenue, supporting a robust pipeline and future growth.
Commercial and production models are being optimized, including modifications to the Takeda Trintellix collaboration.
Latest events from H. Lundbeck
- Upgraded guidance and late-stage catalysts support the 2027–2029 scale phase.LUN
Jefferies Global Healthcare Conference - Vyepti-led growth and stronger earnings lifted FY 2026 guidance as leverage fell.LUN
Q3 2026 - Vyepti-led growth lifted 9M results and FY 2026 guidance as leverage fell to 0.7x.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026